What is Formation Bio?
Formation Bio is a technology-driven pharmaceutical entity that distinguishes itself through a radically more efficient approach to drug development. The company has engineered a sophisticated technology platform designed to optimize crucial aspects of clinical drug trials. This platform facilitates more effective trial design, expedites trial completion timelines, and enhances the quality of the resulting trial data. Formation Bio strategically acquires clinical-stage drugs from established pharmaceutical and biotech firms. Its core objective is to expedite the development of these acquired assets, thereby accelerating the delivery of novel therapies to patients and maximizing the value derived from each program.
How much funding has Formation Bio raised?
Formation Bio has raised a total of $372M across 1 funding round:
Series D
$372M
Series D (2024): $372M with participation from Andreessen Horowitz, Sanofi, Sequoia Capital, and Emerson Collective
Key Investors in Formation Bio
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in both early-stage startups and established growth companies, likely bringing strategic guidance and operational expertise to Formation Bio's development.
Sanofi
Sanofi, a global biopharmaceutical company, offers deep industry insight and potential strategic alignment, focusing on discovering, developing, and delivering medicines across various therapeutic areas.
Sequoia Capital
Sequoia Capital is a long-term investor with a track record of partnering with entrepreneurs to create market leaders, likely providing significant strategic support and capital for Formation Bio's expansion.
What's next for Formation Bio?
With the infusion of major strategic investment, Formation Bio is poised to further enhance its drug development platform and expand its pipeline of clinical-stage assets. This substantial backing, particularly from prominent venture capital firms and strategic corporate investors, signals strong confidence in the company's innovative model and its potential to disrupt traditional pharmaceutical development timelines. The company is likely to focus on scaling its operations, advancing its acquired drug candidates through critical clinical milestones, and potentially exploring new therapeutic areas or strategic partnerships to broaden its impact on patient care.
See full Formation Bio company page
